Authors
Latest:
BCMA-Targeting Agents for the Treatment of Multiple Myeloma Take HoldAcross therapy vehicles, agents targeting the B-cell maturation antigen have emerged as promising potential therapies in the multiple myeloma treatment paradigm. Following the 2019 American Society of Hematology Annual Meeting & Exposition, experts reflect on what these new advances mean for the field of oncology care.
Latest:
Potential for Systemic Therapy in the Adjuvant Setting of HCCMasatoshi Kudo, MD, PhD, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma. While current trials are investigating this therapy in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.
Latest:
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast CancerHeather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Latest:
Differences Observed in Urinary Microbiota Among Patients With Bladder CancerMassimo Lazzari, MD, discusses findings from an analysis of the urinary microbiota in patients with bladder cancer.
Latest:
The Potential of Antibody-Drug Conjugates in the Treatment of Breast CancerTargeted therapy through the use of antibody–drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.
Latest:
PRRT Effective and Safe as Salvage Therapy for GEP and Bronchial NETsTumor response rates after initial treatment with peptide receptor radionuclide therapy have proven clinical benefit; however, complete response is uncommon.
Latest:
Behind the RUBY Trial of Dostarlimab and Chemo for Endometrial CancerMatthew A. Powell, MD, discusses the methods and design of the randomized, double-blind, phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial in endometrial cancer.
Latest:
Chemotherapy-Related Adverse Events Versus Immunotherapy-Related Adverse EventsMatthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Latest:
Managing Side Effects of Chemotherapy in Patients With Gynecologic CancersMatthew Carlson, MD, discusses his take home message for managing symptoms of chemotherapy in patients with gynecologic cancers.
Latest:
Dr. Matthew Cooperberg on Surgery for Aggressive Prostate CancerCooperberg says a growing body of evidence dictates that surgery in prostate cancer may be a more effective local therapy than radiation alone.
Latest:
Current and Future Trends in the Bladder Cancer Treatment ParadigmMatthew Galsky, MD, discusses the future of bladder cancer research and the impact of new treatments such as immune checkpoint inhibitors and antibody-drug conjugates.
Latest:
Nivolumab With Ipilimumab for Small Cell Lung CancerMatthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study, which explored nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).
Latest:
Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRCMatthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.
Latest:
Surprising Findings With Nivolumab in Bladder Cancer TrialsMatthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder cancer compared with trials of similar agents.
Latest:
Future Directions of Lasofoxifene Research in Breast CancerMatthew P. Goetz, MD, discusses the next steps for evaluating treatment with lasofoxifene.
Latest:
Dr. Taylor Discusses the Toxicities and Impact of Lenvatinib in the SELECT TrialMatthew H. Taylor, MD, Oregon Health and Science University, discusses the toxicities and impact of lenvatinib in the SELECT trial, which treated patients with 131I-refractory differentiated thyroid cancer.
Latest:
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast CancerMatthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer.
Latest:
The Rationale for Bemcentinib Plus Pembrolizumab in AXL-Positive NSCLCMatthew Krebs, MBChB, PhD, explains the rationale for a phase II study of bemcentinib, a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced non–small cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer Annual Meeting.
Latest:
Treatments on the Horizon in NETsMatthew Kulke, MD, director, Neuroendocrine and Carcinoid Tumors Program, Dana-Farber Cancer Institute, discusses treatment options on the horizon in the treatment of neuroendocrine tumors (NETs) during the 2017 NANETS Symposium.
Latest:
Durable CR With Lasofoxifene in ESR1+, ER+/HER2- Metastatic Breast CancerMatthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the findings from the ELAINE-1 trial.
Latest:
The Evolving Castration-Resistant Prostate Cancer Treatment LandscapeMathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.
Latest:
Long-Term Results of Ibrutinib/Umbralisib Show Efficacy in CLL and MCLMatthew S. Davids, MD, discusses the long-term follow-up of a phase 1/1b trial for patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma receiving ibrutinib and umbralisib.
Latest:
Using Combination Therapy for Patients With Relapsed/Refractory MCLMatthew Davids, MD, MMSc, discusses the prognosis expected for patients with mantle cell lymphoma, as well as chronic lymphocytic leukemia, in the relapsed/refractory population.
Latest:
The Potential Link Between Genetic Mutations and Colorectal CancerMatthew Yurgelun, MD, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer, as well as the next steps in identifying these mutations.
Latest:
Ongoing Trial of Abemaciclib and Pembrolizumab in HR+/HER2-Negative Breast CancerMaura N. Dickler, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an ongoing clinical trial of the CDK4/6 inhibitor abemaciclib combined with the PD-L1 inhibitor pembrolizumab (Keytruda) for patients with hormone receptor (HR)-positive, HER2-negative breast cancer. She also sheds light on abemaciclib's unique mechanism of action.
Latest:
Discussing ICIs in Endometrial Cancer for Cancer Immunotherapy MonthMaurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.
